A clinical rating scale for progressive supranuclear palsy

被引:477
作者
Golbe, Lawrence I.
Ohman-Strickland, Pamela A.
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ 08840 USA
[2] Univ Med & Dent New Jersey, Sch Publ Hlth, Brunswick, NJ USA
关键词
progressive supranuclear palsy; validity; longitudinal; Steele-Richardson-Olszewski; rating scale;
D O I
10.1093/brain/awm032
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We devised a Progressive Supranuclear Palsy (PSP) Rating Scale comprising 28 items in six categories: daily activities (by history), behaviour, bulbar, ocular motor, limb motor and gait/midline. Scores range from 0 to 100, each item graded 0-2 (six items) or 0-4 (22 items). Inter-rater reliability is good, with intra-class correlation coefficient for the overall scale of 0.86 (95% Cl 0.65-0.98). A single examiner applied the PSPRS at every visit for 162 patients. Mean rate of progression was 11.3 (11.0) points per year. Neither onset age nor gender correlated well with rate of progression. Median actuarially corrected survival was 73 years. The PSPRS score was a good independent predictor of subsequent survival (P < 0.0001). For example, for patients with scores from 40 to 49, 3-year survival was 41.9% (95% Cl 31.0-56.6) but 4-year survival was only 179% (95% Cl 10.2-31.5). For those patients, likelihood or retaining some gait function was 51.7% (40.0-66.9) at I year but only 6.5% (1.8-23.5) at 3 years. We conclude that the PSPRS is a practical measure that is sensitive to disease progression and could be useful as a dependent variable in observational or interventional trials and as an indicator of prognosis in clinical practice.
引用
收藏
页码:1552 / 1565
页数:14
相关论文
共 25 条
[1]  
Cubo E, 2000, MOVEMENT DISORD, V15, P276, DOI 10.1002/1531-8257(200003)15:2<276::AID-MDS1010>3.0.CO
[2]  
2-Q
[3]   Natural history and clinical features of progressive supranuclear palsy: a clinical study [J].
Diroma, C ;
Dell'Aquila, C ;
Fraddosio, A ;
Lamberti, S ;
Mastronardi, R ;
Russo, I ;
De Mari, M ;
Iliceto, G .
NEUROLOGICAL SCIENCES, 2003, 24 (03) :176-177
[4]   Progression of gait, speech and swallowing deficits in progressive supranuclear palsy [J].
Goetz, CG ;
Leurgans, S ;
Lang, AE ;
Litvan, I .
NEUROLOGY, 2003, 60 (06) :917-922
[5]  
Golbe L, 2005, NEURODEGENER DIS, P663
[6]  
Golbe Lawrence I., 1997, Neurology, V48, pA326
[7]   PREVALENCE AND NATURAL-HISTORY OF PROGRESSIVE SUPRANUCLEAR PALSY [J].
GOLBE, LI ;
DAVIS, PH ;
SCHOENBERG, BS ;
DUVOISIN, RC .
NEUROLOGY, 1988, 38 (07) :1031-1034
[8]  
KLAWANS HL, 1971, EUR NEUROL, V5, P115
[9]   Pharmacological therapy in progressive supranuclear palsy [J].
Kompoliti, K ;
Goetz, CG ;
Litvan, I ;
Jellinger, K ;
Verny, M .
ARCHIVES OF NEUROLOGY, 1998, 55 (08) :1099-1102
[10]   Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: A clinicopathological study [J].
Litvan, I ;
Mangone, CA ;
McKee, A ;
Verny, M ;
Parsa, A ;
Jellinger, K ;
DOlhaberriague, L ;
Chaudhuri, KR ;
Pearce, RKB .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 60 (06) :615-620